Executive Profiles

Tommy Bramley and Kristine Flemister discuss today’s increasingly complex healthcare environment, and share insights into how stakeholders should be evolving to better help patients and providers navigate barriers around access and affordability.

DIA’s global chief executive talks with Pharm Exec about the current trajectory of patient-centric product development and the need to establish common pathways and metrics to best harness its benefits in everyday practice.

Though challenges in space and affordability remain, New York City is emerging as a hotspot for biotech incubators, including one unique startup based in the city’s fast-growing innovation center, whose CEO, like many C-suite veterans, made the career leap from the big pharma world to forging new discoveries in medical science.

Roche's Marcus Gerund is working to bring healthcare to some of the poorest areas of the world.

While the field of regenerative medicine has grown considerably since the ’90s-in innovation and acceptance-entrenched companies such as Athersys are looking to forge new advances in the stem cell arena by transforming promising science into real-world treatments.

Raman Sehgal talks to three industry leaders for their insights on the challenges faced across the life science sector and how the EMA needs to respond.

At this month's AMPLEXOR Life Sciences’ “Be The Expert” conference, Pharm Exec caught up with Steve Gens, who talked about the evolution of Regulatory Information Management (RIM) and offered some predictions for 2022.

Ilyssa Levins talks to Pharm Exec about some of the regulatory, compliance and legal challenges posed by the digital health revolution.

IBM Watson Health's Peter Brandsetter talks about how analytics, IoT and artficial intelligence are moving from buzz words to real-world solutions with benefits that weren't possible just a few years ago.

Rani Therapeutics CEO Mir Imran recounts the lessons he's learned in founding more than 20 life sciences companies and developing more than 400 patents.

Dr. Ann Aerts, head of the Novartis Foundation, Switzerland talks with Pharm Exec about the Novartis Foundation initiatives.

A former biology major, biotech investment banker, and venture capitalist, Tim Sullivan brings that sought-after melding of business and scientific perspectives to his role as chief financial officer for Apellis, a clinical-stage drug company hopeful of ushering in novel protein inhibitors form autoimmune disease.

CEO Helen Torley talks to Pharm Exec about her vision for Halozyme as a multi-product oncology biotech.

To coincide with World Immunization Week, IFPMA's Thomas Cueni, chair of the AMR Industry Alliance, outlines the critical importance of vaccines in the fight against AMR and infectious diseases.

From her early calling as a doctor to assuming critical leadership roles at the front lines of the world’s most pressing population health issues, Julie Gerberding, this year's Healthcare Businesswomen’s Association Woman of the Year, has remained steadfast in her life’s mission-help the many, help the one.

Executives from diagnostics, payer, pharma, and patient care companies converge to share the inside scoop on outcomes-based contracting.

Pharm Exec speaks to James Burt, Accord Healthcare’s executive vice president, Europe and MENA, about the company’s vision for the UK and Europe post-Brexit, the challenges of retaining the company’s culture amid major growth, and the current landscape for generic medicines.

Saurabh Saha, Senior Vice President and Global Head of Translational Medicine at BMS, shares his perspectives on the current biomarker landscape, the role of translational medicine, and how BMS is working to advance biomarker research across their R&D portfolio.

How one pharma vet helped create the first industry-wide training standards for aspiring medical affairs professionals. 

Markus Warmuth, CEO of cancer genomics company H3 Biomedicine, speaks with Pharm Exec about being part of a new wave of biotech business leaders, who let the science chart the course.

Pharm Exec speaks to Jane Griffiths, Global Head of Actelion, about the current state of the industry's reputation and the work that needs to be done to further build trust with patients and the public.

Richard Lajoie, the new head of Valeant Canada, shares his main priorities for the business, including growing its domestic manufacturing as a key cog globally.

Molly Harper, vice president of commercial development at Akcea Therapeutics, outlines best practices for this unique group of therapies

Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer-starting with Gleveec and continuing with last year’s approval of the first-ever CAR-T cell therapy-touching on the related broader issues such as pricing and value and new innovations in cancer science.

Tracy Rockney and Rob Merrill talk about their free regulatory compliance and information platform MyIndago, and why they think the industry needs it now.

A quick-fire interview with J&J’s Joanne Waldstreicher about the company’s “Advancing the Safe Use of Healthcare Products QuickFire Challenge”.

Julia Cheek recently landed in the television history books when she accepted a $1 million offer on the TV show “Shark Tank," the largest valuation for a solo female entrepreneur in the show’s history.

Sean McCarthy, President & CEO of CytomX, outlines the company’s journey from university startup to rising star of the immuno-oncology space.

Drawing from his research roots and the leadership lessons gained in melding business and culture in geographies across the globe, Ruud Dobber is busy steering AstraZeneca’s US course as it navigates the complexities of a fast-evolving therapeutic market.

Andrew Lane, EVP, Established Pharmaceuticals at Abbott, tells Pharm Exec how understanding emerging market dynamics can explain why branded generic medicines are important.